This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morris, L. F. Articles by Braunstein, G. D. Search for Related Content PubMed PubMed Citation Articles by Morris, L. F. Articles by Braunstein, G. D.

The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in ¹³¹I-Scanned and Nonscanned Individuals

Departments of Medicine and Nuclear Medicine, Cedars-Sinai Medical Center-University of California School of Medicine, Los Angeles, California 90048

Address all correspondence and requests for reprints to: Glenn D. Braunstein, M.D., Department of Medicine, 8700 Beverly Boulevard, Room 2119, Los Angeles, California 90048. E-mail: braunstein{at}cshs.org

Abstract

Thyroid stunning has been reported as the temporary impairment of thyroid tissue after a 111-MBq or greater diagnostic ¹³¹I dose that decreases the final absorbed dose in ablative therapy. Concerns regarding the reality of stunning have arisen in part due to a flawed study design in prior reports. To assess whether a stunning effect has any impact on therapeutic outcomes, we compared initial treatment ablation rates in patients who received 111- to 185-MBq ¹³¹I diagnostic scans (n = 37) before ablative doses of 3700–7400 MBq with ablation rates in patients who did not receive any ¹³¹I before the initial treatment dose (n = 63). Ablation rates were 64.9% for scanned patients and 66.7% for nonscanned patients, a nonsignificant difference. Nonscanned patients with metastatic lesions (n = 23) were ablated at a higher rate (78.3%) than scanned patients (n = 9) (66.7%), but the difference was not significant (P = 0.50). It is possible that the reported stunning phenomenon, specifically its impact in temporarily impairing tissue, has been overemphasized.

This article has been cited by other articles:

				K. P. Donahue, N. P. Shah, S. L. Lee, and M. E. Oates Initial Staging of Differentiated Thyroid Carcinoma: Continued Utility of Posttherapy 131I Whole-Body Scintigraphy Radiology, March 1, 2008; 246(3): 887 - 894. [Abstract] [Full Text] [PDF]

				E. B. Silberstein Comparison of Outcomes After 123I Versus 131I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma J. Nucl. Med., July 1, 2007; 48(7): 1043 - 1046. [Abstract] [Full Text] [PDF]

				C. Lundh, M. M. Norden, M. Nilsson, and E. Forssell-Aronsson Reduced Iodide Transport (Stunning) and DNA Synthesis in Thyrocytes Exposed to Low Absorbed Doses from 131I In Vitro J. Nucl. Med., March 1, 2007; 48(3): 481 - 486. [Abstract] [Full Text] [PDF]

				A. Hackshaw, C. Harmer, U. Mallick, M. Haq, and J. A. Franklyn 131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 28 - 38. [Abstract] [Full Text] [PDF]

				J. C. Sisson, A. M. Avram, S. A. Lawson, P. G. Gauger, and G. M. Doherty The So-Called Stunning of Thyroid Tissue J. Nucl. Med., September 1, 2006; 47(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				C. Ma, A. Kuang, J. Xie, and T. Ma Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning J. Nucl. Med., September 1, 2005; 46(9): 1473 - 1480. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF]

				A F Leger, M Pellan, F Dagousset, A Chevalier, I Keller, and J Clerc A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments Br. J. Radiol., May 1, 2005; 78(929): 428 - 432. [Abstract] [Full Text] [PDF]

				S. K. Gerard and H. Q. Dam Stunning with 131I Diagnostic Whole-Body Imaging of Patients with Thyroid Cancer * Dr Dam responds: Radiology, March 1, 2005; 234(3): 972 - 974. [Full Text] [PDF]

				H. Q. Dam, S. M. Kim, H. C. Lin, and C. M. Intenzo 131I Therapeutic Efficacy Is Not Influenced by Stunning after Diagnostic Whole-Body Scanning Radiology, August 1, 2004; 232(2): 527 - 533. [Abstract] [Full Text] [PDF]

				M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners Impact of 131I Diagnostic Activities on the Biokinetics of Thyroid Remnants J. Nucl. Med., April 1, 2004; 45(4): 619 - 625. [Abstract] [Full Text] [PDF]

				R. J. Robbins, S. M. Larson, N. Sinha, A. Shaha, C. Divgi, K. S. Pentlow, R. Ghossein, and R. M. Tuttle A Retrospective Review of the Effectiveness of Recombinant Human TSH as a Preparation for Radioiodine Thyroid Remnant Ablation J. Nucl. Med., November 1, 2002; 43(11): 1482 - 1488. [Abstract] [Full Text] [PDF]

				P. Postgard, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nystrom, E. Forssell-Aronsson, and M. Nilsson Stunning of Iodide Transport by 131I Irradiation in Cultured Thyroid Epithelial Cells J. Nucl. Med., June 1, 2002; 43(6): 828 - 834. [Abstract] [Full Text] [PDF]

				W. Brenner Is Thyroid Stunning a Real Phenomenon or Just Fiction? J. Nucl. Med., June 1, 2002; 43(6): 835 - 836. [Full Text] [PDF]

				V. Fatourechi, I. D. Hay, H. Javedan, G. A. Wiseman, B. P. Mullan, and C. A. Gorman Lack of Impact of Radioiodine Therapy in Tg-Positive, Diagnostic Whole-Body Scan-Negative Patients with Follicular Cell-Derived Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1521 - 1526. [Abstract] [Full Text] [PDF]